Setting Up an IRB Protocol for Retatrutide: A Step-by-Step Overview for Clinic Owners

An IRB-approved research protocol is the gold standard legal framework for clinical engagement with investigational compounds like retatrutide. It is not a workaround — it is the actual legal mechanism that authorizes human administration of investigational drugs. Here is what setting one up actually requires.

You have two options: an institutional IRB affiliated with a hospital or university, or an independent (commercial) IRB. For most private practices, an independent IRB is the practical choice. Independent IRBs are accredited, experienced with clinical research protocols, and set up to work with practices that are not affiliated with academic medical centers.

The protocol is the core document. It must describe:

• The research question you are investigating.
• The patient population (inclusion and exclusion criteria).
• The intervention — what you are administering, at what dose, by what route, on what schedule.
• The monitoring procedures — how you will track patient response and adverse events.
• The adverse event reporting procedures — what you will report, to whom, and on what timeline.
• The data collection and analysis plan.

This is a substantive document. It requires input from a qualified medical director and, ideally, review by healthcare counsel.

The informed consent document must accurately describe the investigational nature of the compound, the known and unknown risks, the patient's right to withdraw, and what will happen to their data. Generic consent forms are not adequate.

The IRB will review your protocol and consent document, may request revisions, and will issue an approval letter when satisfied. This process typically takes four to eight weeks for an initial submission.

Once approved, you can begin enrolling research participants under the protocol. You must follow the protocol as approved, submit progress reports on the IRB's schedule, and report adverse events promptly.

Setting up an IRB protocol requires real investment — time, expertise, and ongoing commitment. But it is the investment that provides genuine legal protection and genuine competitive differentiation for practices that want to engage with investigational compounds like retatrutide.

Related reading: IRB Enrollment for Practices · IRB Studies Overview · Building a Legally Defensible Position